Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. Earnings land in 7 days, which usually moves targets. How we score this
19 firms currently rating it, weighted by track record.
The 18 firms with a track record here beat the S&P 40% of the time over 12 months.
Pro: see the crowd-vs-sharp split for AMGNAnalysts rate Amgen Hold, with 14 buy-or-stronger ratings against 3 sell ratings across 29 firms; the consensus price target of $356.69 sits below the current $376.26. UBS maintained a Buy rating on July 13, while Morgan Stanley and Guggenheim held Equal-Weight and Neutral stances respectively in recent weeks. The biotech giant trades at a forward P/E of 16.05 with 5.80% revenue growth and a notably high ROE of 101.32%, though leverage sits elevated at a 6.24 debt-to-equity ratio.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 13, 2026 | UBS | ○ Maintained | |
| Jul 13, 2026 | Guggenheim | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free